Ambrx Biopharma Inc. AMAM NYSE

Ambrx Biopharma Inc. (AMAM) reported total assets of $146.98M and total liabilities of $29.13M for fiscal year 2022, resulting in total equity of $117.85M.

The company held $84.48M in cash and short-term investments. Total debt stood at $11.98M, with net debt of $-43.63M. The Debt-to-Equity (D/E) ratio was 0.1 (conservative).

Current ratio is 5.44, indicating strong short-term liquidity. Interest coverage is -59x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (58/100) — Total assets $146.98M and equity $117.85M support the company's competitive scale

Overall SharesGrow Score: 28/100 with 0/7 criteria passed.

DAWN

Day One Biopharmaceuticals, Inc.

$21.47

+0.05%

VECT

VectivBio Holding AG

$16.87

+0.12%

IMMX

Immix Biopharma, Inc.

$10.04

+1.93%

ZURA

Zura Bio Limited

$5.69

-0.52%

INZY

Inozyme Pharma, Inc.

$4.00

+0.25%

ABOS

Acumen Pharmaceuticals, Inc.

$2.72

+1.49%

XFOR

X4 Pharmaceuticals, Inc.

$4.33

+3.10%

ELEV

Elevation Oncology, Inc.

$0.37

-2.12%